What’s New: A new research indicates a new medication, known as BG-12, may prevent relapsing of multiple sclerosis in some people.
Important Detail: In one study, participants were divided into 4 groups – 359 participants took 240mg of BG-12 two times a day, 345 took 240mg thrice a day, 350 took glatiramer acetate and 363 took placebo. The annual relapse rate among them was 0.22, 0.20, 0.29 and 0.40 respectively. But their rate of disability progression was comparable.
In another study, 410 participants took BG-12 two times a day, 416 took the drug thrice a day and 408 participants took placebo. The annual relapse rate among them was 0.17, 0.19 and 0.36. However, in this study, rates of disability progression among three groups were 16%, 18% and 27% respectively.
Conclusion: Timothy Coetzee from National Multiple Sclerosis Society explained that these studies indicated that new strategies can proved to be effective at tackling immune system by showing the potential of another oral treatment.